Hope Medicine

Hope Medicine Inc., based in China, has announced the first patient dosing in a global Phase II clinical trial for its monoclonal antibody (mAb) HMI-115, which targets the prolactin receptor (PRL R). The study aims to evaluate HMI-115 as a treatment for endometriosis in Chinese patients. In April 2019, Hope…